Tenmile’s Post

New mpox vaccine shows breakthrough safety & efficacy in preclinical trials - Tonix's TNX-801 protects against lethal infection with single dose, proves safe at high doses in immunocompromised subjects. For daily news and analysis subscribe to the https://lnkd.in/gFNEJAhc newsletter. #Pharmaceuticals #Healthcare #Biotech

CanSino Biologics (SEHK:6185, SHSE:688185) announced that the Indonesian Food and Drug Authority has granted approval to begin Phase 1/2 clinical trials for the company's recombinant polio vaccine candidate (CS-2036). These trials will evaluate the vaccine's safety and immunogenicity in specific age groups of infants. Developed using CanSino Biologics' advanced protein design and virus-like particle (VLP) technology, CS-2036 is a non-infectious vaccine that doesn't rely on live viruses during production. This innovative approach not only ensures a strong safety profile but also makes it a promising candidate for global polio eradication, as recommended by the World Health Organization. CS-2036 also has the potential to be integrated into combination vaccines, contributing to broader immunization efforts. #Biotechnology #VaccineDevelopment #PolioEradication #GlobalHealth #ClinicalTrials #Innovation #HealthcareInnovation #QimingPortfolio #QimingHealthcare 

On this World Polio Day, we reaffirm our commitment to the global fight against polio. For decades, pharmaceutical innovations and widespread vaccination efforts have brought us closer to eradicating this debilitating disease. At Kings Global Biotech Limited, we are proud to play a part in developing safe and effective vaccines that contribute to a healthier, polio-free world. Together, we can ensure that future generations live without the threat of polio. Let’s continue the journey toward global eradication and make history in healthcare. #WorldPolioDay #EndPolioNow #VaccinesSaveLives #GlobalHealth #PharmaCommitment #HealthcareInnovation #PharmaManufacturing #QualityFirst #ThirdPartyManufacturing #TrustedPharmaPartner #PharmaSolutions #ManufacturingExcellence #InnovationInPharma #CommitmentToHealth #LeadershipInHealth #HealthcareJourney #InnovationInPharma #CommitmentToHealth #LeadershipInHealth #Kingsglobal #Biotech #pharmaceuticals #indiangenerics #pharmaceuticalindustry #pharmamanufacturing #makeinindia #cphi #oncology #contractmanufacturing

🌟 **Breaking News in the Biopharmaceutical World! 🌟** Exciting Announcement Alert! 🎉 The World Health Organization (WHO) has just prequalified the first vaccine against MPOX! 🦠✨ Curious to know more about this groundbreaking development and what it means for global healthcare? Dive into our latest blog post where we explore the implications, significance, and future prospects of this milestone in biopharmaceutical history. 🔗 Read the full article here: https://lnkd.in/dkKuEpf7 Stay informed, stay inspired, and join the conversation on the latest advancements in the fight against MPOX. Your insights matter! #Biopharmaceuticals #WHO #VaccineInnovation #MPOX #BlogPost #HealthcareAdvancements

An experimental mRNA vaccine against Mpox developed by Moderna (mRNA-1769) outperformed in animal studies the live virus attenuated vaccine by Jynneos. The new mRNA vaccine, which carries the information to generate four Mpox viral immunogens, protected macaques, and animals displayed less viral lesions than those administered with the attenuated vaccine. The mRNA vaccine also shortened the period during which the animals exhibited lesions by more than 10 days as compared to Jynneos vaccine. Moderna’s vaccine has now entered Phase 1 clinical trials. #monkeypox #mpox  #health #globalhealth #publichealth #outbreak #medicine #biotechnology #pharmaceuticals #infectiousdiseases #WHO #CDC #FDA #ECDC #Africa #moderna #vaccines https://lnkd.in/g6JMrb2Q

Recent Approvals of drugs #1 The European Commission (EC) has granted marketing authorization for VELSIPITY® (etrasimod) in the European Union to treat patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) #2 The EC has granted marketing authorization for PREVENAR 20®, for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age. #3 The EC has granted marketing authorization for EMBLAVEO® (aztreonam-avibactam) for the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTI), including pyelonephritis. It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options. #4 The U.S. Food and Drug Administration (FDA) has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX) prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var) capsid as detected by an FDA-approved test. The FDA approved the supplemental Biologics License Application (sBLA) granting full approval for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy

Sanofi and the Ontario Government | Gouvernement de l’Ontario are thrilled to announce the grand opening of Sanofi's new $800 million vaccine manufacturing facility in Toronto! This state-of-the-art facility, spanning 200,000 square feet, will boost production of life-saving vaccines for pertussis, diphtheria, and tetanus, ensuring increased access to vaccines domestically and globally. 💼 Premier Doug Ford expressed his support, emphasizing the facility's importance in Ontario's growing life sciences sector. With 200 new jobs and significant government investment, this expansion underscores Ontario's position as a life sciences superpower. 💉 Sanofi's commitment to Ontario extends further with plans for a second facility, aiming to increase production of the Fluzone High-Dose Influenza Vaccine. Together, these initiatives champion health care innovation and build healthier communities worldwide. 🔬 Ontario's investment in life sciences continues with $15 million through the Life Sciences Innovation Fund and $100 million through the Ontario Together Fund, reinforcing the province's position as a global biomanufacturing and life sciences hub. #Sanofi #LifeSciences #HealthcareInnovation

Excited to share our latest publication on COVID-19 therapeutics and vaccines! 🦠💉 Joshua Gini, Olumuyiwa Ariyo, ugorexeze Eze In our recent book chapter (Chapter 18), we explored the critical role of repurposed drugs and vaccines in combating the global pandemic. We delved into the evidence supporting the efficacy of medications like dexamethasone, hydroxychloroquine, and ivermectin, as well as the impact of different vaccine types (DNA, mRNA, and non-replicating viral vector). Key findings: Hydroxychloroquine and Lopinavir/ritonavir: Ineffective in treating COVID-19. Ivermectin: Promising early results, but further research was needed. Dexamethasone: Significantly reduced mortality in severe cases. Vaccines: Proven effective in curtailing the pandemic. Remember the initial confusion and craze surrounding various COVID-19 treatments? This chapter sheds light on the efficacy of these approaches. Of course!! I would vote vaccines as the best invention for outbreaks since 1796😊 But once again, what can we learn from using what we have while exploring solutions. #COVID19 #Pharmacology #Treatment #Vaccines #PublicHealth #MedicalResearch

🌍💉 The Future of Vaccines: A Glimpse into a Healthier Tomorrow 💉🌍 In an age where emerging viral diseases seem to appear more frequently, it’s hard not to imagine a future reminiscent of horror movies. But amid this growing concern, there’s a beacon of hope: the relentless work being done by pharmaceutical companies worldwide. As we face new challenges posed by these pathogens, innovation in vaccine development is more critical than ever. The promise of cutting-edge research and technology means we are better equipped to tackle potential health catastrophes, ultimately safeguarding global public health. Let's embrace the advancements in vaccine technology and support the scientists and pharmaceutical leaders dedicated to protecting our future. 💪 Curious about the latest trends in vaccine development? Check out this insightful article: Vaccine Development Trends (https://lnkd.in/dsjVjdm7) #Vaccines #PublicHealth #Innovation #Pharmaceuticals #FutureOfHealthcare #Biotech #GlobalHealth

--> The Asia Pacific region (excluding COVID-19 vaccines) is anticipated to grow at significant CAGR during the forecast period. <-- --> Download PDF Brochure for More Details@ https://lnkd.in/dM6udwdh The Asia Pacific (excluding COVID-19 vaccines) is accounted to be the fastest-growing segment of the market. Rapid population growth and urbanization, particularly in countries like China and India, are driving increased demand for vaccines to combat infectious diseases. Additionally, rising healthcare expenditure and government initiatives aimed at improving vaccination coverage further stimulate market growth. Additionally, the growing prevalence of infectious diseases coupled with increasing awareness about preventive healthcare measures is driving vaccine uptake in the region. --> Global Leading Companies: GSK Merck Pfizer Sanofi CSL Emergent BioSolutions Johnson & Johnson AstraZeneca Serum Institute of India Pvt. Ltd. Bavarian Nordic Mitsubishi Tanabe Pharma America Daiichi Sankyo US Panacea Biotec Biological E. Limited Bharat Biotech among others....!